Laurence Rulleau

Dr. Laurence Terrisse Rulleau, PhD, brings 25 years of experience in investing in life sciences and building companies in the sector. Dr Laurence Terrisse Rulleau has been a partner with the CTI Life Sciences fund since 2014 where she has played a key role in the fund’s investments but more specifically in the creation of 6 new companies in Quebec: Dalcor, a spin-off of the Montreal Heart Institute; Ilkos, a spin-off of Servier, Precithera based on innovative science, Find Therapeutics, created from the granting of asset licenses from the University of Chicago and the purchase of assets of a French company.

More recently, Dr Rulleau has lead the investment in Epitopea a new company created as a spin-off of IRICOR and In Dtx Biotherapeutics, a company focusing in immune-oncology. Dr. Rulleau also led the investment in Profound Medical and was an observer on the board of Directors of Visterra, a Boston-based biotechnology company acquired in August 2018 by Otsuka Pharmaceuticals.